Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cocrystal Pharma Inc (NQ: COCP )

1.730 -0.040 (-2.26%)
Streaming Delayed Price Updated: 3:11 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cocrystal Pharma Inc

< Previous 1 2 3 Next >
Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
Via ACCESSWIRE
COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024
COCP stock results show that Cocrystal Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024
COCP stock results show that Cocrystal Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Recap: Cocrystal Pharma Q4 Earnings
Via Benzinga
Recap: Cocrystal Pharma Q3 Earnings
Via Benzinga
Analyst Ratings for Cocrystal Pharma
Via Benzinga
Why Cocrystal Pharma Shares Are Trading Higher Today
Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company completed a $4 million private placement. 
Via Benzinga
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023
COCP stock results show that Cocrystal Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
$2M Bet On Cocrystal Pharma? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday. 
Via Benzinga
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Gainers PLx Pharma Inc. (NASDAQ: PLXP) jumped 149.6% to $0.2623 in pre-market trading after dropping over 13% on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a... 
Via Benzinga
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal... 
Via Newsfile
Exposures COVID-19
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A
Via Benzinga
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma to Participate in Two Investor Conferences in November
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. 
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results. 
Via Benzinga
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma to Present at the LD Micro Main Event XV
From Cocrystal Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.